Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Klinisk undersøkelse av Tsert SI-systemet, modell NG SI IMT 3X hos pasienter med aldersrelatert makuladegenerasjon i sluttstadiet

24. september 2026 oppdatert av: VisionCare, Inc.

En prospektiv, multisenter post-markedsføring klinisk undersøkelse av Tsert SITM-systemet, modell NG SI IMT 3X hos pasienter med sentral synsnedsettelse assosiert med aldersrelatert makuladegenerasjon i sluttstadiet

The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD).

Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

This is an interventional, prospective, multicenter, open label, single group assignment Post-Market Clinical Follow-up (PMCF) study in men and women >=55 years with central vision impairment associated with end-stage AMD.

Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study. Baseline visual acuity of the study subjects will be assessed with a 2.8X external telescope simulator (ETS) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts to determine if they are likely to benefit from receiving the IMT. To be included in the study and to proceed with the surgery, subjects must achieve, using the ETS, at least a one line (5 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. Subjects not meeting these criteria will be excluded from the study.

If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery.

Postoperatively, the surgeon will complete a usability and satisfaction questionnaire after each implantation procedure.

The patients will undergo ophthalmic evaluations in both eyes at regular intervals for up to 12 months. The subjects will also be required to undergo 6 to 10 additional visits for vision training with a low vision specialist.

Surgical complications, as well as all Adverse Event (AEs) and use of medications will be monitored from baseline to the end of the study.

Studietype

Intervensjonell

Registrering (Faktiske)

68

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Brussels, Belgia
        • UZ Brussel
      • Marseille, Frankrike
        • Centre d'Ophtalmologie Paradis-Monticelli
      • Saint-Jean-de-Luz, Frankrike
        • Hélios Ophtalmologie, Saint-Jean-de-Luz
      • Strasbourg, Frankrike
        • CHRU de Strasbourg
      • Dublin, Irland
        • Mater Misericordiae University Hospital
      • Naples, Italia
        • Università degli Studi di Napoli Federico II
      • Roma, Italia
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Alicante, Spania
        • VISSUM
      • Barcelona, Spania
        • Institut OMIQ
      • Madrid, Spania
        • Hospital Universitario La Luz - Quirónsalud
      • Belfast, Storbritannia
        • Royal Victoria Hospital Belfast Health & Social Care Trust
      • Karlsruhe, Tyskland
        • Augenklinik Städtisches Klinikum Karlsruhe
      • Münster, Tyskland
        • Universitätsklinikum Münster Klinik für Augenheilkunde

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Be 55 years of age or older.
  2. Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT.
  3. Have evidence of cataract.
  4. Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR) and no worse than 20/800 (1.6 LogMAR) in both eyes.
  5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.
  6. Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using Samsara's 2.8X external telescope simulator (ETS, supplied separately).
  7. Have an ACD of at least 2.5 mm in the eye scheduled for surgery.
  8. Be willing to participate in a post-operative training program for the use of the NG SI IMT 3X implant.
  9. Review and sign the Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) prior to any study-related procedures being performed.
  10. Have adequate understanding of the local language to understand verbal and written subject information and be willing to comply with the study requirements.

Exclusion Criteria:

  1. Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.

  2. Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.

  3. A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP>22 mm Hg.

  4. Corneal guttata.

  5. Known sensitivity to post-operative medications.

  6. Significant communication impairment or severe neurological disorders.

  7. Have undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes.

  8. An ocular condition that predisposes the patient to eye rubbing.

  9. Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3X implant surgery.

  10. Patients for whom the planned operative eye has:

    • Myopia > 6.0 D
    • Hyperopia > 4.0 D
    • Axial length < 21 mm
    • Endothelial cell density < 1600 cells per square mm
    • Narrow angle, i.e., < Schaffer grade 2.
  11. Inflammatory ocular disease.

  12. Cornea stromal or endothelial dystrophies, including guttata.

  13. Zonular weakness/instability of crystalline lens, or pseudoexfoliation.

  14. Diabetic retinopathy.

  15. Untreated retinal tears.

  16. Retinal vascular disease.

  17. Optic nerve disease.

  18. A history of retinal detachment.

  19. Retinitis pigmentosa.

  20. Intraocular tumor.

  21. Have received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study.

  22. Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative.

  23. Have a condition or be in a situation that, in the Investigator's opinion, may put the Subject at significant risk, may confound the study results, or may interfere significantly with the Subject's participation in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SING IMT System model NG SI IMT 3X

All participants will be implanted with the SING IMT System model NG SI IMT 3X.

The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system
Tidsramme: 12 months

The percent decrease in endothelial cell density (ECD).

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incision size needed for device implantation
Tidsramme: 12 moths

Incision size will not exceed 8.0 mm (non-inferiority assumption) in 75% of surgeries

12 moths
Surgical complications
Tidsramme: 12 moths

AEs and serious adverse events

12 moths
Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes.
Tidsramme: 12 months

Near and distance BCVA will show an improvement of ≥2 lines in the ETDRS chart in at least 50% (non-inferior to 50%) of the implanted eyes at 12 months post implantation.

12 months
Usability of SING IMT System, including delivery system
Tidsramme: 12 months

Surgeon will complete a usability and satisfaction questionnaire

12 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Device stability and fixation
Tidsramme: 12 months

Assessed by slit lamp biomicroscopy examination: device tilt and device decentration

12 months
Post-operative anterior chamber depth (ACD)
Tidsramme: 12 months

Anterior Chamber Depth (ACD) evaluated by ultrasound biomicroscopy (UBM), ocular coherence tomography (OCT) or another applicable test method

12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. september 2022

Primær fullføring (Antatt)

1. mai 2027

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

3. mars 2021

Først innsendt som oppfylte QC-kriteriene

11. mars 2021

Først lagt ut (Faktiske)

15. mars 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere